Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01753349 · ClinicalTrials.gov registry record
Phase IV-Cervical Dystonia-INTEREST IN CD2
A clinical trial, sponsored by Ipsen.
- Completed
- Registry status
- 1,050
- Enrollment target
NCT01753349: Completed study, sponsored by Ipsen.
NCT01753349 is a clinical trial that has completed, run by Ipsen. The registered enrollment target is 1,050 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01753349 has completed, sponsored by Ipsen.
- COMPLETED
- Registry status
- 1,050 participants
- Enrollment target
Study Summary
The purpose of the study is to document long-term response in real-life practice after injection cycles with BoNT-A in subjects suffering from idiopathic cervical dystonia (Long-term clinical and pharmaco-economic data).
Primary Outcome
Identification of prognostic factors for subject's satisfaction regarding control of symptoms associated with idiopathic CD.
Interventions
- BIOLOGICAL Botulinum toxin type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,050 participants |
| Start Date | 2012-12 |
| Est. Completion | 2017-09-25 |
What the finished NCT01753349 record still lists
NCT01753349 is an observational study that tracks outcomes without assigning an intervention. Its 1,050 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Botulinum toxin type A is the first listed.
NCT01753349 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01753349 about?
NCT01753349 is a clinical study titled "Phase IV-Cervical Dystonia-INTEREST IN CD2". The purpose of the study is to document long-term response in real-life practice after injection cycles with BoNT-A in subjects suffering from idiopathic cervical dystonia (Long-term clinical and pharmaco-economic data).
What is the current status of trial NCT01753349?
This trial is currently completed. The enrollment target is 1,050 participants. The study started on 2012-12. Estimated completion is 2017-09-25.
What interventions are being tested in trial NCT01753349?
The interventions under investigation include: Botulinum toxin type A (BIOLOGICAL).
Who is sponsoring clinical trial NCT01753349?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04505618 · 1,050 participants · NA
Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease
- NCT04511806 · 1,050 participants
Childhood Cancer Predisposition Study (CCPS)
- NCT05028972 · 1,050 participants · NA
Hearing Impairment, Strategies and Outcomes in VA Emergency Departments
- NCT05915377 · 1,050 participants · NA
Researching Efficient Approaches to Delirium Identification-Sustaining Effective Translation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia